Titan Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011

Global Markets Direct, October 2011, Pages: 54

Titan Pharmaceuticals, Inc. – Product Pipeline Review – H2 2011

Summary

Global Market Direct’s pharmaceuticals report, “Titan Pharmaceuticals, Inc. - Product Pipeline Review - H2 2011” provides data on the Titan Pharmaceuticals, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Titan Pharmaceuticals, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Titan Pharmaceuticals, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Titan Pharmaceuticals, Inc. - Brief Titan Pharmaceuticals, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Titan Pharmaceuticals, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Titan Pharmaceuticals, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Titan Pharmaceuticals, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Titan Pharmaceuticals, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Titan Pharmaceuticals, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Titan Pharmaceuticals, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Titan Pharmaceuticals, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Titan Pharmaceuticals, Inc. and identify potential opportunities in those areas.

Keywords

Current R&D Portfolio of Titan Pharmaceuticals, Inc.; Titan Pharmaceuticals, Inc. - Key Therapeutics; Titan Pharmaceuticals, Inc. - Pipeline Overview and Promising Molecules; Titan Pharmaceuticals, Inc. - News; Titan Pharmaceuticals, Inc. - Latest Updates; Titan Pharmaceuticals, Inc. - Pipeline; Titan Pharmaceuticals, Inc. - Discontinued/Dormant Projects

List of Tables
List of Figures
Titan Pharmaceuticals, Inc. Snapshot
Titan Pharmaceuticals, Inc. Overview
Key Information
Key Facts
Titan Pharmaceuticals, Inc. – Research and Development Overview
Key Therapeutic Areas
Titan Pharmaceuticals, Inc. – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Combination Treatment Modalities
Titan Pharmaceuticals, Inc. – Pipeline Products Glance
Titan Pharmaceuticals, Inc.–Early Stage Pipeline Products
Pre-Clinical Products/Combination Treatment Modalities
Titan Pharmaceuticals, Inc. – Drug Profiles
ProNeura + Apomorphine
Product Description
Mechanism of Action
R&D Progress
Titan Pharmaceuticals, Inc. – Pipeline Analysis
Titan Pharmaceuticals, Inc. – Pipeline Products by Therapeutic Class
Titan Pharmaceuticals, Inc. - Pipeline Products By Target
Titan Pharmaceuticals, Inc. – Pipeline Products by Route of Administration
Titan Pharmaceuticals, Inc. – Pipeline Products by Molecule Type
Titan Pharmaceuticals, Inc. – Recent Pipeline Updates
Titan Pharmaceuticals, Inc. - Dormant Projects
Titan Pharmaceuticals, Inc. - Discontinued Pipeline Products
Discontinued Pipeline Product Profiles
DITPA
Gallium Maltolate
Titan Pharmaceuticals, Inc. – Locations And Subsidiaries
Head Office
Recent Developments
Oct 31, 2008: Titan Pharmaceuticals Provides Update On Probuphine Patent Application
Mar 31, 2010: Titan Initiates Confirmatory Phase III Study Of Probuphine For Treatment Of Opioid Addiction
Nov 30, 2009: Titan Recieves Notice Of Allowance For Probuphine Patent Application In The Treatment Of Opiate Addiction
Jun 30, 2011: Titan Pharmaceuticals Provides Update On Confirmatory Phase III Study Of Probuphine
Sep 22, 2010: Titan Completes Patient Enrollment In Phase III Study Of Probuphine For Treatment Of Opioid Addiction
Sep 22, 2003: Titan Announces Results From Study Of Gallium Maltolate In Patients With Advanced Paget's Disease
Oct 20, 2011: Titan Announces Probuphine Presentation At American Society of Addiction Medicine Conference
Nov 19, 2008: Titan Pharmaceuticals Presents Phase 3 Data For Probuphine At The 2008 International Society Of Addiction Medicine Congress
Nov 17, 2010: Titan Presents Phase III Probuphine Data At Society For Neuroscience Annual Meetings
Jun 17, 2011: Titan Pharmaceuticals Provides Additional Details On Confirmatory Phase III Study Of Probuphine
Jun 17, 2011: Titan Pharmaceuticals Provides Update On Confirmatory Phase III Study Of Probuphine
Aug 16, 2011: Titan Pharmaceuticals Provides Additional Positive Results In Confirmatory Phase III Trial Of Probuphine
Jun 16, 2010: Titan Receives Probuphine Patent From USPTO
Nov 12, 2003: Titan's Proneura Technology Prevents Onset of Motor Complications In Validated Parkinson's Disease Model
Oct 12, 2010: Titan Announces Journal Of American Medical Association Publication Of Phase III Probuphine Data
Jul 11, 2011: Titan Pharmaceuticals Announces Positive Top Line Results In Confirmatory Phase III Trial Of Probuphine
Nov 09, 2007: Titan Completes A Phase I Dose Escalation Study Of Gallium Maltolate In Cancer Patients
Mar 07, 2006: Titan Initiates Controlled Phase II Clinical Study Of DITPA In The Treatment Of Elevated Cholesterol Levels
Dec 05, 2006: Titan Pharmaceutical's Gallium Compound May Offer Treatment For Lymphoma Patients With Resistant Disease
Oct 04, 2009: Titan Announces Award Of NIH Grant For Probuphine Clinical Development
Aug 03, 2010: Titan Completes More Than 60% Of Patient Enrollment In Phase III Study Of Probuphine For Treatment Of Opioid Addiction
Apr 02, 2001: Titan Pharmaceuticals Initiates Phase II Clinical Testing Of Gallium Maltolate For The Treatment Of Prostate Cancer And Multiple Myeloma
Oct 01, 2009: Titan Announces Award Of NIH Grant For Probuphine Clinical Development
Financial Deals Landscape
Titan Pharmaceuticals, Inc., Deals Summary
Titan Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deal Details
Equity Offering
Titan Pharmaceuticals Completes Private Placement Of $21.28 Million
Titan Pharmaceuticals Completes Private Placement Of $1 Million
Titan Pharmaceuticals Completes Private Placement Of $11 Million
Titan Pharmaceuticals Completes Private Placement Of $10 Million
Titan Pharmaceuticals Completes Private Placement Of $15 Million
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Titan Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Titan Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Titan Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011
Titan Pharmaceuticals, Inc. - Pipeline By Therapeutic Class, H2 2011
Titan Pharmaceuticals, Inc. - Pipeline By Target, H2 2011
Titan Pharmaceuticals, Inc. – Pipeline By Route of Administration, H2 2011
Titan Pharmaceuticals, Inc. – Pipeline By Molecule Type, H2 2011
Titan Pharmaceuticals, Inc. – Recent Pipeline Updates, H2 2011
Titan Pharmaceuticals, Inc. - Dormant Developmental Projects, 2010
Titan Pharmaceuticals, Inc. - Discontinued Pipeline Products, 2010
Titan Pharmaceuticals, Inc., Deals Summary
Titan Pharmaceuticals Completes Private Placement Of $21.28 Million
Titan Pharmaceuticals Completes Private Placement Of $1 Million
Titan Pharmaceuticals Completes Private Placement Of $11 Million
Titan Pharmaceuticals Completes Private Placement Of $10 Million
Titan Pharmaceuticals Completes Private Placement Of $15 Million

List of Figures
Titan Pharmaceuticals, Inc. – Pipeline by Therapy Area and Indication, H2 2011
Titan Pharmaceuticals, Inc. – Pipeline by Stage of Development, H2 2011
Titan Pharmaceuticals, Inc. – Combination Treatment Modalities in Pipeline, H2 2011

Customers who bought this item also bought

• Top Five Global Software Companies: Performance, Strategies and Competitive Analysis
• Apple, Inc. - Strategies, Financial Outlook and Competitive Benchmark Analysis
• eBay - Strong Execution
• Scientific Games Corporation - Company Analysis
• Hewlett-Packard Company - Strategies, Financial Outlook and Competitive Benchmark Analysis
• Amazon - Point of Realization in 2013?
• Ixia - Company Analysis
• SunGard - Profile - US
• Insight into Samsung Electronics' Notebook PC Business Model
• US - Accenture - Company Profile